

**Mr. Colin Carrie:**

With regard to purchases of COVID-19 vaccine doses by the government: has the government purchased any doses before the doses being approved by Health Canada, and, if so, what are the details of all such purchases, including the (i) manufacturer, (ii) name of the vaccine, (iii) date of purchase, (iv) number of doses purchased, (v) date of the approval by Health Canada?

**Mr. Adam van Koeverden (Parliamentary Secretary to the Minister of Health and to the Minister of Sport, Lib.):**

Mr. Speaker, Canada built its vaccine portfolio through advance purchase agreements, or APAs, securing future access to COVID-19 vaccines in development at a time when it was not yet known which vaccine candidates would receive Health Canada authorization, and if so, when. This was done in order to ensure that Canada was at the forefront of receiving life-saving vaccines at the height of the COVID-19 pandemic, while providing suppliers the opportunity to accelerate product development and production capacity, and to engage in the regulatory process. Vaccine candidates were selected with guidance from the COVID-19 vaccine task force, experts who helped identify a diverse portfolio of different vaccine types that were most likely to be effective and delivered the fastest.

The first two agreements, with Moderna and Pfizer, were announced in August 2020, followed by similar agreements with Janssen for Johnson & Johnson, Novavax, Sanofi and GlaxoSmithKline, AstraZeneca/Verity Pharmaceuticals and Serum Institute of India, and Medicigo. The agreements included firm commitments to purchase doses as well as access to optional doses should they be required.

Companies began submitting data to Health Canada for regulatory review as early as September 2020. The ability to review data from early development while later-stage clinical trials are under way expedites the regulatory review process.

Before filing a submission for a continuing review, sponsors of clinical trials are expected to have gathered a certain level of evidence on the safety, quality and efficacy of their vaccine. Vaccine applications are reviewed through an independent process and products are authorized based on scientific rigour and medical evidence. Products are not made available for use in the Canadian market until they have received regulatory approval.

Vaccine agreements with suppliers are as follows. For AstraZeneca Vaxzevria COVID-19 vaccine, the manufacturer is AstraZeneca Canada Inc. The date the initial agreement was publicly announced was May 17, 2020. The number of doses purchased was 20 million, and the date of initial approval by Health Canada was February 26, 2021.

For Covishield, the manufacturer is Verity Pharmaceuticals Canada Inc./Serum Institute of India, in collaboration with AstraZeneca Canada Inc. The date the initial agreement was publicly announced was February 26, 2021. The number of doses purchased was two million, and the date of initial approval by Health Canada was February 26, 2021. The authorization expired September 16, 2021.

For Moderna Spikevax COVID-19 vaccine, the manufacturer is Moderna. The date the initial agreement was publicly announced was November 16, 2020. The number of doses purchased was 44 million. The initial agreement, after some options exercised,

amendment for 2022-24 was up to 25 million in 2022, up to 35 million in 2023 and up to 35 million in 2024. The date of initial approval by Health Canada was December 23, 2020.

For Pfizer-BioNTech Comirnaty COVID-19 vaccine, the manufacturer was BioNTech Manufacturing GmbH. The date the initial agreement was publicly announced was July 20, 2020. The number of doses purchased was 51 million. The initial agreement, after some options exercised, amendment for 2022-24 was up to 65 million for 2022, up to 60 million in 2023 and up to 60 million in 2024. The date of initial approval by Health Canada was December 09, 2020.

For Janssen Jcovden COVID-19 vaccine, the manufacturer was Janssen Inc., or Johnson & Johnson. The date the initial agreement was publicly announced was August 14, 2020. The number of doses purchased was up to 38 million, and the date of initial approval by Health Canada was March 5, 2021.

For Medicago Covifenz COVID-19 vaccine, the manufacturer was Medicago Inc. The date the initial agreement was publicly announced was October 23, 2020. The number of doses purchased was up to 76 million, and the date of initial approval by Health Canada was February 24, 2022.

For Novavax Nuvaxovid COVID-19 vaccine, the manufacturer was Novavax Inc. The date the initial agreement was publicly announced: August 14, 2020. The number of doses purchased was up to 76 million, and the date of initial approval by Health Canada was February 17, 2022.

For the Sanofi vaccine, the manufacturer was Sanofi. The date initial agreement was publicly announced was July 29, 2020. The number of doses purchased was up to 72 million, and it is still under review by Health Canada.  
[English]